Idiopathic chronic pancreatitis: Beyond antioxidants

Area of Science:

• Gastroenterology and Hepatology
• Pharmacology
• Genetics

Background:

• Chronic pancreatitis (CP) presents complex etiopathogenesis with increasing idiopathic cases and changing phenotypes.
• Current understanding of CP pathogenesis is incomplete, hindering effective cures.
• The efficacy of antioxidant therapies for CP remains controversial, as they do not significantly reduce inflammatory markers.

Discussion:

• Statins, initially linked to pancreatitis risk, show potential benefits in CP, particularly lipophilic variants like simvastatin and lovastatin.
• Hydrophilic statins such as rosuvastatin appear less effective than lipophilic ones for CP.
• N-acetylcysteine is emerging as a promising therapeutic agent for CP.

Key Insights:

• Idiopathic chronic pancreatitis incidence and phenotypes are changing.
• Antioxidant therapies show limited benefit in modulating CP's inflammatory and fibrotic processes.
• Lipophilic statins and N-acetylcysteine demonstrate potential for CP treatment.

Outlook:

• Further research is needed to elucidate the precise mechanisms of CP and identify targeted therapies.
• Repurposing existing drugs like statins and N-acetylcysteine offers a promising avenue for CP management.
• Investigating gene-environment interactions is crucial for understanding and preventing CP.